Powered by

Gamida Cell Reports Second Quarter 2020 Financial Results and Provides Company Update; - Secondary endpoints from positive Phase 3 study of omidubicel and initiation of BLA submission expected in the fourth quarter of 2020; Expanded access program for omi

Aug 11, 2020 - Business Wire
Board and Executive Moves-Financial Results

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today reported financial results for the quarter ended June 30, 2020. The company also highlighted progress with omidubicel , an advanced cell therapy in Phase 3 clinical development as a potentially life-saving treatment option for patients in need of bone marrow transplant, and GDA-201 , a natural killer (NK) cell immunotherapy in Phase 1 development in pat...